• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《沉默在诉说,但我们置若罔闻:凝血酶原基因最后外显子中同义 c.1824C>T 基因变异是一种新的血栓形成风险因素》。

The Silence Speaks, but We Do Not Listen: Synonymous c.1824C>T Gene Variant in the Last Exon of the Prothrombin Gene as a New Prothrombotic Risk Factor.

机构信息

Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.

Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.

出版信息

Clin Chem. 2020 Feb 1;66(2):379-389. doi: 10.1093/clinchem/hvz015.

DOI:10.1093/clinchem/hvz015
PMID:32040579
Abstract

BACKGROUND

Thrombosis is a major global disease burden with almost 60% of cases related to underlying heredity and most cases still idiopathic. Synonymous single nucleotide polymorphisms (sSNPs) are considered silent and phenotypically neutral. Our previous study revealed a novel synonymous FII c.1824C>T variant as a potential risk factor for pregnancy loss, but it has not yet been associated with thrombotic diseases.

METHODS

To determine the frequency of the FII c.1824C>T variant we have sequenced patients' DNA. Prothrombin RNA expression was measured by quantitative PCR. Functional analyses included routine hemostasis tests, western blotting and ELISA to determine prothrombin levels in plasma, and global hemostasis assays for thrombin and fibrin generation in carriers of the FII c.1824C>T variant. Scanning electron microscopy was used to examine the structure of fibrin clots.

RESULTS

Frequency of the FII c.1824C>T variant was significantly increased in patients with venous thromboembolism and cerebrovascular insult. Examination in vitro demonstrated increased expression of prothrombin mRNA in FII c.1824T transfected cells. Our ex vivo study of FII c.1824C>T carriers showed that the presence of this variant was associated with hyperprothrombinemia, hypofibrinolysis, and formation of densely packed fibrin clots resistant to fibrinolysis.

CONCLUSION

Our data indicate that FII c.1824C>T, although a synonymous variant, leads to the development of a prothrombotic phenotype and could represent a new prothrombotic risk factor. As a silent variant, FII c.1824C>T would probably be overlooked during genetic screening, and our results show that it could not be detected in routine laboratory tests.

摘要

背景

血栓形成是一种主要的全球性疾病负担,其中近 60%的病例与潜在遗传有关,大多数病例仍然是特发性的。同义单核苷酸多态性(sSNP)被认为是沉默的,表型上是中性的。我们之前的研究表明,一种新的同义 FII c.1824C>T 变体可能是妊娠丢失的潜在风险因素,但尚未与血栓性疾病相关。

方法

为了确定 FII c.1824C>T 变体的频率,我们对患者的 DNA 进行了测序。通过定量 PCR 测量凝血酶原 RNA 的表达。功能分析包括常规止血试验、western blot 和 ELISA 以确定 FII c.1824C>T 变体携带者血浆中的凝血酶原水平,以及用于检测凝血酶和纤维蛋白生成的全局止血试验。扫描电子显微镜用于检查纤维蛋白凝块的结构。

结果

FII c.1824C>T 变体的频率在静脉血栓栓塞和脑血管损伤患者中显著增加。体外研究表明,FII c.1824T 转染细胞中凝血酶原 mRNA 的表达增加。我们对 FII c.1824C>T 携带者的体外研究表明,该变体的存在与高凝血酶原血症、低纤维蛋白溶解和形成密集的纤维蛋白凝块有关,这些凝块对纤维蛋白溶解有抗性。

结论

我们的数据表明,尽管 FII c.1824C>T 是一种同义变体,但它导致了血栓形成表型的发展,可能代表了一种新的血栓形成风险因素。作为一种沉默变体,FII c.1824C>T 在遗传筛查期间可能会被忽视,我们的结果表明,它不能在常规实验室测试中检测到。

相似文献

1
The Silence Speaks, but We Do Not Listen: Synonymous c.1824C>T Gene Variant in the Last Exon of the Prothrombin Gene as a New Prothrombotic Risk Factor.《沉默在诉说,但我们置若罔闻:凝血酶原基因最后外显子中同义 c.1824C>T 基因变异是一种新的血栓形成风险因素》。
Clin Chem. 2020 Feb 1;66(2):379-389. doi: 10.1093/clinchem/hvz015.
2
Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers.活化蛋白 C 反应率升高可降低因子 V 莱顿携带者的血栓形成风险,但不能降低凝血酶原 20210G>A 携带者的血栓形成风险。
Circ Res. 2019 Aug 16;125(5):523-534. doi: 10.1161/CIRCRESAHA.119.315037. Epub 2019 Jul 17.
3
Clinical and biochemical characterization of the prothrombin Belgrade mutation in a large Serbian pedigree: new insights into the antithrombin resistance mechanism.在一个大型塞尔维亚家族中对凝血酶原贝城突变的临床和生化特征进行研究:对抗凝血酶抵抗机制的新见解。
J Thromb Haemost. 2017 Apr;15(4):670-677. doi: 10.1111/jth.13618. Epub 2017 Feb 24.
4
Routine coagulation tests are not useful as a screening tool for the FII G20210A polymorphism.常规凝血试验作为FII G20210A基因多态性的筛查工具并无用处。
Clin Lab. 2014;60(10):1725-33. doi: 10.7754/clin.lab.2014.140215.
5
The 3'end prothrombin gene variants in patients with different thrombotic events.不同血栓形成事件患者的凝血酶原基因3'端变体
Lab Med. 2014 Fall;45(4):309-14. doi: 10.1309/LM8E84ZSLPDMWZCM.
6
[The effect of FII c.1787G>A (prothrombin Belgrade) mutation on prothrombin gene expression in vitro].[FII基因c.1787G>A(凝血酶原贝尔格莱德突变)对凝血酶原基因体外表达的影响]
Mol Biol (Mosk). 2017 Jan-Feb;51(1):59-63. doi: 10.7868/S0026898416060070.
7
Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.静脉血栓栓塞症后 G20210A 凝血酶原突变携带者的血浆纤维蛋白凝块特性:利伐沙班的影响。
Thromb Haemost. 2017 Aug 30;117(9):1739-1749. doi: 10.1160/TH17-01-0060. Epub 2017 Aug 3.
8
Comparative evaluation of five different methods for the measurement of plasma factor II levels in carriers of the 20210A prothrombin variant.20210A 凝血酶原变异携带者血浆因子 II 水平测量的五种不同方法的比较评估
Blood Coagul Fibrinolysis. 2002 Jul;13(5):465-70. doi: 10.1097/00001721-200207000-00013.
9
Screening and functional exploration of prothrombin Arg596 related mutations in Chinese venous thromboembolism patients.筛查并研究中国静脉血栓栓塞症患者凝血酶原 Arg596 相关突变。
J Clin Pathol. 2018 Jul;71(7):614-619. doi: 10.1136/jclinpath-2017-204888. Epub 2018 Jan 13.
10
AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms.AB0血型与因子V莱顿突变或凝血酶原G20210A多态性携带者发生静脉或动脉血栓形成的风险
Haematologica. 2008 May;93(5):729-34. doi: 10.3324/haematol.12271. Epub 2008 Apr 2.

引用本文的文献

1
Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study.有效抗风湿治疗可恢复早期类风湿关节炎患者受损的凝血参数:一项前瞻性试点研究。
RMD Open. 2024 Dec 31;10(4):e004838. doi: 10.1136/rmdopen-2024-004838.
2
Genetic factors, risk prediction and AI application of thrombotic diseases.血栓性疾病的遗传因素、风险预测及人工智能应用
Exp Hematol Oncol. 2024 Aug 27;13(1):89. doi: 10.1186/s40164-024-00555-x.
3
Synonymous variants that disrupt messenger RNA structure are significantly constrained in the human population.
同义变体如果破坏了信使 RNA 的结构,在人类群体中会受到显著的限制。
Gigascience. 2021 Apr 5;10(4). doi: 10.1093/gigascience/giab023.